AbbVie   4Q Revenues: $6.4 billion (+17%) 4Q Earnings: $1.5 billion (loss of $810 million 4Q14) FY Revenues: $22.9 billion (+15%) FY Earnings: $5.1 billion (+190%) Comments: Humira revenues were $3.7 billion in the quarter, up 11%. Growth in the quarter was also driven by Imbruvica sales of $343 million, Viekira sales of $554 million, and Creon sales of $185 million. Lupron sales were $235 million, up 13%. Synagis sales were down 11% to $266 million. Kaletra sales were down 9% to $...